New Accelerated Approval Withdrawal Process More Streamlined, Marks Says

 
• By Derrick Gingery
  
multiple myeloma
Pepaxto is the third product that used accelerated approval to gain market entry and then be withdrawn through FDA regulation. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards